Register or Sign in to Save this opportunity, or Send an Inquiry.
Acellular Animal Vaccine for Bordetella Bronchiseptica-mediated Respiratory Infections (Ref # WFU 08-11)
Wake Forest Innovations United States flag United States
Abstract ID:
The novel BcfA accellular vaccine can efficiently elicit protective immune responses against Bordetella respiratory infections without risking subsequent infection by the vaccine strain and disease, as is the case with commercially available vaccines.
Send an Inquiry
RE:
Participants
You

Acellular Animal Vaccine for Bordetella Bronchiseptica-mediated Respiratory Infections


Value Proposition


This novel BcfA accellular vaccine can efficiently elicit protective immune responses without the risk of subsequent infection by the vaccine strain and disease, as is the case with the present commercially available vaccines for Bordetella respiratory infections.


Invention Summary


Inventors in the Microbiology and Immunology Department at Wake Forest School of Medicine have developed an acellular B. bronchiseptica vaccine comprised of the immunogenic BcfA (Bordetella colonization factor A) protein, which with remarkable efficacy establishes protective immunity in vivo against Bordetella infections.
Proof of concept has been established in an in vivo mouse model, and both passive and active immunization have been shown to induce complete protection from bordetellosis, greatly decreased bacterial burden, high antibody titers and markedly reduced pulmonary injury.


Competitive Benefits



GO PREMIUM TO GET PATENT INFORMATION
Type of Business Relationship Sought

Exclusive Licensing Arrangement

Possibility of a parallel Sponsored Research Agreement

 

FEATURED
Last Updated Jan 2014
Technology Type THERAPEUTIC
Phase of Development EARLY STAGE
CORPORATION

Opportunity Contact